DE69830301T2 - Modulatoren von insulinrezeptor-aktivität - Google Patents

Modulatoren von insulinrezeptor-aktivität Download PDF

Info

Publication number
DE69830301T2
DE69830301T2 DE69830301T DE69830301T DE69830301T2 DE 69830301 T2 DE69830301 T2 DE 69830301T2 DE 69830301 T DE69830301 T DE 69830301T DE 69830301 T DE69830301 T DE 69830301T DE 69830301 T2 DE69830301 T2 DE 69830301T2
Authority
DE
Germany
Prior art keywords
insulin
receptor
independently
compound
insulin receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69830301T
Other languages
German (de)
English (en)
Other versions
DE69830301D1 (de
Inventor
M. Lawrence KAUVAR
Richard Sportsman
O. Hugo VILLAR
R. Wayne SPEVAK
A. Ron KOHANSKI
Apparao Satyam
Ryan Koehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telik Inc
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/784,857 external-priority patent/US5830918A/en
Priority claimed from US08/784,854 external-priority patent/US5851988A/en
Priority claimed from US08/916,088 external-priority patent/US6329431B1/en
Application filed by Telik Inc filed Critical Telik Inc
Publication of DE69830301D1 publication Critical patent/DE69830301D1/de
Application granted granted Critical
Publication of DE69830301T2 publication Critical patent/DE69830301T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69830301T 1997-01-15 1998-01-15 Modulatoren von insulinrezeptor-aktivität Expired - Fee Related DE69830301T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US784857 1985-10-04
US784854 1991-10-30
US78485597A 1997-01-15 1997-01-15
US784855 1997-01-15
US08/784,857 US5830918A (en) 1997-01-15 1997-01-15 Nonpeptide insulin receptor agonists
US08/784,854 US5851988A (en) 1997-01-15 1997-01-15 Nonpeptide insulin receptor agonists
US82526997A 1997-03-27 1997-03-27
US825269 1997-03-27
US08/916,088 US6329431B1 (en) 1997-01-15 1997-08-21 Nonpeptide insulin receptor agonists
US916088 1997-08-21
PCT/US1998/000801 WO1998032017A2 (en) 1997-01-15 1998-01-15 Modulators of insulin receptor activity

Publications (2)

Publication Number Publication Date
DE69830301D1 DE69830301D1 (de) 2005-06-30
DE69830301T2 true DE69830301T2 (de) 2006-02-02

Family

ID=27542207

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69830301T Expired - Fee Related DE69830301T2 (de) 1997-01-15 1998-01-15 Modulatoren von insulinrezeptor-aktivität

Country Status (9)

Country Link
EP (1) EP0960335B1 (enExample)
JP (1) JP2002512685A (enExample)
AT (1) ATE296446T1 (enExample)
AU (1) AU6026698A (enExample)
CA (1) CA2278023A1 (enExample)
DE (1) DE69830301T2 (enExample)
DK (1) DK0960335T3 (enExample)
ES (1) ES2242995T3 (enExample)
WO (1) WO1998032017A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
EP1115847A1 (en) 1998-09-25 2001-07-18 Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
TWI234557B (en) * 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
US7181349B1 (en) * 1999-05-27 2007-02-20 Cecil Yip Identification of compounds for modulating dimeric receptors
ITTO20000745A1 (it) * 1999-07-29 2002-01-28 Telik Inc Nuovi acidi naftilsolfonici e composti ad essi correlati utli come agonisti dell'assorbimento del glucosio.
FR2797767B1 (fr) * 1999-08-27 2002-06-14 Centre Nat Rech Scient Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
EP1383793B1 (en) * 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Insulin and igf-1 receptor agonists and antagonists
WO2002055664A2 (en) * 2001-01-12 2002-07-18 Exelixis, Inc. Modulating insulin receptor signaling
CN101103977A (zh) * 2002-06-05 2008-01-16 株式会社医药分子设计研究所 糖尿病治疗药
TW200410671A (en) * 2002-06-05 2004-07-01 Inst Med Molecular Design Inc Medicines for inhibiting the activation of AP-1
CN1658855B (zh) 2002-06-06 2010-04-28 株式会社医药分子设计研究所 O-取代羟基芳基衍生物
CN1658872B (zh) * 2002-06-06 2010-09-22 株式会社医药分子设计研究所 抗过敏药
EP1535610A4 (en) * 2002-06-10 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC CANCER
EA010470B1 (ru) * 2002-06-10 2008-08-29 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
DE10323081A1 (de) * 2003-05-22 2004-12-16 Aventis Pharma Deutschland Gmbh Verwendung eines Polypeptides
JP2008542685A (ja) * 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023231A1 (en) * 1994-02-28 1995-08-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cell lines for the identification of substances affecting insulin receptor mediated signal transduction
WO1996030762A1 (en) * 1995-03-31 1996-10-03 Merck & Co., Inc. Insulin mimetic and enhancer assay

Also Published As

Publication number Publication date
DE69830301D1 (de) 2005-06-30
EP0960335B1 (en) 2005-05-25
AU6026698A (en) 1998-08-07
EP0960335A2 (en) 1999-12-01
WO1998032017A2 (en) 1998-07-23
ES2242995T3 (es) 2005-11-16
CA2278023A1 (en) 1998-07-23
DK0960335T3 (da) 2005-06-20
ATE296446T1 (de) 2005-06-15
JP2002512685A (ja) 2002-04-23
WO1998032017A3 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
DE69830301T2 (de) Modulatoren von insulinrezeptor-aktivität
DE69408541T2 (de) Kinaserezeptoraktivierungstest
DE69936453T2 (de) Für einen g-protein gekoppelten rezeptor, der an der empfindungstransduktion beteiligt ist, kodierende nukleinsäuren
DE69233572T2 (de) Screening-Verfahren für Kalzium-Rezeptor aktive Verbindungen
DE4122886C2 (de) Diagnostischer Kit für die Diagnose und Charakterisierung von Brustschmerzen bei ihrem ersten Auftreten
DE69821475T2 (de) Verwendung von eindimensionaler kernspinresonanz fur identifizierung von liganden fur ziel-biomolekule
DE69837015T2 (de) Verfahren zur Stabilisierung und Messung von Troponinkomplexen
DE2754086B2 (de) Spezifisches Bindungsverfahren zum Nachweis und zur Bestimmung eines Liganden in einem flüssigen Medium
DE69218981T2 (de) Verfahren zum Nachweis freier IGF-I, IGF-II, und GH Spiegel in Körperflüssigkeiten
JP2004523726A (ja) コンフォメーションに敏感な結合ペプチドの同定方法およびその利用
EP0089008A2 (de) Hochspezifisches Antiserum gegen Prokollagen-Peptid Col 1 (Typ III) und Prokollagen-Peptid (Typ III), seine Herstellung und Verwendung.
Williams et al. Subtype specificity of α-adrenergic receptors in rat heart
DE3751316T2 (de) Materialzusammensetzung, welche ein Polypeptid aus Pankreas-Insel-Amyloid und/oder Antikörpern gegen dieses Polypeptid enthält, und Anwendung dieser Zusammensetzung.
DE69019375T2 (de) Verfahren zur detektion von knochen- und anderen bindegewebeerkrankungen bei menschen und tieren.
DE69613146T3 (de) Verwendung von kernspinresonanz zur bestimmung von liganden für zielbiomoleküle
Lefkowitz et al. Plasma membrane receptors.
DE60033183T2 (de) Transplantatabstossung und damit verbundene zustände
CA2414626A1 (en) A method for extracting quantitative information relating to interactions between cellular components
DE60117591T2 (de) Verfahren zum Nachweis von Serin/Threonin-Kinase-Aktivität
US5851988A (en) Nonpeptide insulin receptor agonists
DE2548196A1 (de) Antigene auf basis von methaqualon- hapten sowie deren verwendung
Sporns et al. Potassium ion-and nitric oxide-induced exocytosis from populations of hippocampal synapses during synaptic maturation in vitro
DE2604991A1 (de) Bestimmung von antipyrin
EP0267355B1 (de) Verfahren zum Identifizieren gewebstypischer, unlöslicher Cytoskelettproteine
US6329431B1 (en) Nonpeptide insulin receptor agonists

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee